Cargando…

Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model

Desmopressin (DDAVP), a synthetic peptide analog of vasopressin, is a safe antidiuretic and hemostatic compound that acts as a selective agonist for the vasopressin V2 membrane receptor. It is known that DDAVP can inhibit progression of residual metastatic cells and also improves chemotherapy effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ripoll, Giselle V., Garona, Juan, Pifano, Marina, Farina, Hernan G., Gomez, Daniel E., Alonso, Daniel F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825504/ https://www.ncbi.nlm.nih.gov/pubmed/24122393 http://dx.doi.org/10.1007/s10549-013-2724-6

Ejemplares similares

The novel desmopressin analogue [V(4)Q(5)]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
por: GARONA, JUAN, et al.
Publicado: (2015)

Preclinical Efficacy of [V(4)Q(5)]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
por: Garona, Juan, et al.
Publicado: (2019)

Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial
por: Iseas, Soledad, et al.
Publicado: (2020)

Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
por: Ripoll, Giselle V., et al.
Publicado: (2020)

Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells
por: Pifano, Marina, et al.
Publicado: (2017)

Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma
por: Sobol, Natasha Tatiana, et al.
Publicado: (2021)

A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients
por: Weinberg, Ruth S, et al.
Publicado: (2015)

Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
por: Alonso, D.F, et al.
Publicado: (2011)

Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients
por: Mast, Mirjam E., et al.
Publicado: (2014)

Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer
por: Wang, Neng, et al.
Publicado: (2012)

No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression
por: Förnvik, Daniel, et al.
Publicado: (2013)

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
por: Vangangelt, K. M. H., et al.
Publicado: (2017)

The molecular diversity of Luminal A breast tumors
por: Ciriello, Giovanni, et al.
Publicado: (2013)

Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo
por: Myers, Tashanna, et al.
Publicado: (2008)

Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence
por: Lyes, Matthew A., et al.
Publicado: (2018)

High tumor budding stratifies breast cancer with metastatic properties
por: Salhia, Bodour, et al.
Publicado: (2015)

Molecular characterization and heterogeneity of circulating tumor cells in breast cancer
por: Jakabova, Anna, et al.
Publicado: (2017)

Geometric tumor embolic budding characterizes inflammatory breast cancer
por: Modi, Arnav P., et al.
Publicado: (2022)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients
por: Bingham, Catherine, et al.
Publicado: (2017)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Enrichment of high-grade tumors in breast cancer gene expression studies
por: van Seijen, M., et al.
Publicado: (2017)

Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients
por: Sajdik, Constantin, et al.
Publicado: (2022)

Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis
por: Tiainen, Satu, et al.
Publicado: (2019)

A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer
por: Hollern, Daniel P., et al.
Publicado: (2018)

The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer
por: Jääskeläinen, Minna M., et al.
Publicado: (2023)

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
por: Pfefferle, Adam D., et al.
Publicado: (2015)

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance
por: Kuilman, Midas M., et al.
Publicado: (2022)

DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
por: Ansems, Marleen, et al.
Publicado: (2015)

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
por: Sadanandam, Anguraj, et al.
Publicado: (2012)

CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes
por: Kerekes, Daniel, et al.
Publicado: (2017)

The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4
por: Chen, Wenhu, et al.
Publicado: (2023)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
por: Siddappa, Chidananda M., et al.
Publicado: (2019)

Immune cell quantitation in normal breast tissue lobules with and without lobulitis
por: Degnim, Amy C., et al.
Publicado: (2014)

Numerical and physical modeling of breast cancer based on image fusion and artificial intelligence
por: Dołęga-Kozierowski, Bartosz, et al.
Publicado: (2023)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Paired-like Homeodomain Transcription factor 2 expression by breast cancer bone marrow disseminated tumor cells is associated with early recurrent disease development
por: Pillai, Sreeraj G., et al.
Publicado: (2015)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

Natural history of age-related lobular involution and impact on breast cancer risk
por: Radisky, Derek C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sic4o0cfes0t7gp79f1jlj5em9